Metastatic Colorectal Cancer | MAX (AG0501CR)
A randomised phase II/III study design to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with metastatic colorectal cancer.
Schema
Summary
This is a phase II/III study evaluating the role of Mitomycin C (MMC), Avastin and Xeloda in metastatic colorectal cancer. The primary aim is to determine an optimal low toxicity regimen which could be used in a broad range of patients. Patients for whom fluoropyrimidine monotherapy is considered appropriate will be randomised to receive capecitabine, capecitabine plus bevacizumab or the combination of capecitabine, bevacizumab and MMC.
